This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Abroad (travel likely)RecruitingPHASE1

Conditions

Non-Hodgkin Lymphoma Refractory/ Relapsed · DLBCL - Diffuse Large B Cell Lymphoma · Mantle Cell Lymphoma (MCL) · Follicular Lymphoma ( FL) · Marginal Zone Lymphoma (MZL)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

City of Hope, Duarte, California, United States
Contact: Study coordinator (Elizabeth Budde, MD) · ebudde@coh.org · 626-218-2405
Washington University School of Medicine, St Louis, Missouri, United States
Contact: Study coordinator (Anne Fischer) · afischer@wustl.edu · 314-362-3021
Roswell Park Cancer Institute, Buffalo, New York, United States
Contact: Study coordinator (Francisco Hernandez, MD) · Francisco.Hernandez@RoswellPark.org · 716-845-2300
Tennessee Oncology, Nashville, Tennessee, United States
Contact: Study coordinator (Michael Byrne, DO) · mbyrne@tnonc.com · 888-550-2835
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Contact: Study coordinator (Ajay Gopal, MD) · agopal@uw.edu · 206-606-2037

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Acute Lymphoblastic Leukemia, Adult B-Cell · Acute Lymphoblastic Leukemia, in Relapse · Non-Hodgkin Lymphoma, B-cell

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

Non-hodgkin Lymphoma · Refractory Lymphoma · Chimeric Antigen Receptor T-cell

Abroad (travel likely)RecruitingPHASE1

Xiamen, China

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Acute Lymphoblastic Leukemia · Non-hodgkin Lymphoma

Abroad (travel likely)RecruitingEARLY_PHASE1

Hangzhou, China

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Mantle Cell Lymphoma · Non Hodgkin Lymphoma · Hematologic Malignancy

Abroad (travel likely)RecruitingPHASE2

Houston, United States